Agile Therapeutics to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
August 22 2017 - 7:30AM
Agile Therapeutics, Inc. (Nasdaq:AGRX) a women’s health specialty
pharmaceutical company, announced today that Al Altomari, Chairman
and CEO will present at the Rodman & Renshaw 19th Annual Global
Investment Conference on Tuesday, September 12, 2017 at 9:10 AM ET
in New York.
To access the live and archived webcasts of the
presentation, visit the Investor Relations section of Agile
Therapeutics website at www.agiletherapeutics.com. The webcast will
be archived on Agile Therapeutics website for 60 days following the
event.
About Agile TherapeuticsAgile
Therapeutics is a forward-thinking women's healthcare company
dedicated to fulfilling the unmet health needs of today’s women.
Our product candidates are designed to provide women with
contraceptive options that offer freedom from taking a daily pill,
without committing to a longer-acting method. Our lead product
candidate, Twirla®, (ethinyl estradiol and levonorgestrel
transdermal system), also known as AG200-15, is a once-weekly
prescription contraceptive patch that recently completed Phase 3
trials. Twirla is based on our proprietary transdermal patch
technology, called Skinfusion®, which is designed to provide
advantages over currently available patches and is intended to
optimize patch adhesion and patient wearability. For more
information, please visit the company website at
www.agiletherapeutics.com. Follow Agile on social media:
@agilether. The company may occasionally disseminate material,
nonpublic information on the company website.
About
Twirla®Twirla (ethinyl estradiol and
levonorgestrel transdermal system) or AG200-15 is an
investigational once-weekly prescription contraceptive patch.
AG200-15 is a combined hormonal contraceptive (CHC) patch that
contains the active ingredients ethinyl estradiol (EE), a synthetic
estrogen, and levonorgestrel (LNG), a type of progestin, a
synthetic steroid hormone. Twirla is designed to be applied once
weekly for three weeks, followed by a week without a patch.
Contact:
Mary Coleman - 609-683-1880
Agile Therapeutics (NASDAQ:AGRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Agile Therapeutics (NASDAQ:AGRX)
Historical Stock Chart
From Apr 2023 to Apr 2024